Recent News

• 10.07.2026 - Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
• 10.05.2026 - Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
• 09.09.2026 - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.07.2026 - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.06.2026 - Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
• 08.04.2026 - Pacira BioSciences Reports Second Quarter 2026 Financial Results
• 07.28.2026 - Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
• 07.27.2026 - Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
• 07.22.2026 - Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
• 07.08.2026 - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 10.08.2026 - SC TO-C Written communication relating to an issuer or third party
• 10.08.2026 - SC14D9C Written communication relating to third party tender offer
• 10.08.2026 - 144 Report of proposed sale of securities
• 10.08.2026 - 8-K Current report
• 10.08.2026 - SC TO-C Written communication relating to an issuer or third party
• 10.08.2026 - EX-99.1 EX-99.1
• 08.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.17.2026 - 144 Report of proposed sale of securities
• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.04.2026 - S-8 Securities to be offered to employees in employee benefit plans